MS4A1 and cancer: Intriguingly, some recent studies have demonstrated that some anti-tumor drugs (such as CD20-targeted rituximab), in addition to treating cancers, also show markedly cardioprotective effects, but the specific mechanism has not been clarified (Uchida et al., 2004; Cang et al., 2012; Waldman et al., 2020).